Mifegyne (Mifepristone)

Mifepristone blocks progesterone receptors in the uterus, causing the decidual lining to break down and the embryo to detach. This loss of progesterone support, combined with subsequent prostaglandin‑induced uterine contractions, facilitates the expulsion of gestational tissue.

The dose of Mifegyne is determined by the prescribing clinician based on national guidelines and the patient’s clinical situation. Healthcare professionals prescribe the appropriate amount and schedule, and patients should follow the prescriber’s instructions exactly.

Mifegyne is intended for use to terminate early pregnancy and is not used to treat conditions during an ongoing pregnancy. It is contraindicated in breastfeeding because it may pass into breast milk; women should discuss alternatives with their healthcare provider.

To order Mifegyne, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and required import documentation.

Mifegyne (mifepristone) is the most widely used progesterone receptor antagonist for early medical abortion and is typically combined with misoprostol. Compared with regimens that use misoprostol alone, the combination offers higher efficacy, shorter time to complete abortion, and a more predictable bleeding pattern.

Mifegyne should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product in a dry place and avoid exposure to extreme temperatures or humidity.

Mifegyne is taken orally as a single dose under medical supervision. After ingestion, a prostaglandin analogue is usually administered 24–48 hours later to complete the abortion process. The exact timing and follow‑up are directed by the treating clinician.

Serious risks include heavy or uncontrolled bleeding, infection, severe abdominal pain, and, rarely, uterine rupture. Patients should be monitored closely after administration and instructed to seek immediate medical care if they experience signs of severe hemorrhage, fever, or intense pain.

Mifegyne is contraindicated in individuals with chronic adrenal insufficiency, long‑term corticosteroid therapy, anticoagulant use, intrauterine device in place, or known allergy to mifepristone. It should also not be used beyond 10 weeks gestation or in ectopic pregnancies.